Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ansuvimab - Ridgeback Biotherapeutics

Next Previous
Drug Profile

Ansuvimab - Ridgeback Biotherapeutics

Alternative Names: Ansuvimab-zykl; Ebanga; EboV mAb114; EVB114; mAb 114; VRC EBOMAB092 00 AB

Latest Information Update: 21 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Humabs BioMed; Institute for Research in Biomedicine; National Institute of Allergy and Infectious Diseases; National Institute of Biomedical Research; United States Army Medical Research Institute of Infectious Diseases
  • Developer Ridgeback Biotherapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Glycoprotein inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ebola virus infections

Most Recent Events

  • 13 Jan 2025 Emergent BioSolutions receives contract modification option to continue development collaboration with BARDA on Ansuvimab (Ebanga™) for Ebola virus infections
  • 12 Sep 2024 Emergent BioSolutions plans to submit sBLA to the US FDA for Ebola virus infections
  • 31 Jul 2023 Emergent BioSolutions establishes BARDA with Biomedical Advanced Research and Development Authority for the development of ansuvimab in Ebola virus infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top